Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bolt Biotherapeutics Inc BOLT

Healthcare Biotechnology
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating... see more

Recent & Breaking News (NDAQ:BOLT)

Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 12, 2024

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

GlobeNewswire November 7, 2024

Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm

Accesswire September 6, 2024

The Schall Law Firm Invites Investors To Contribute To A Securities Fraud Lawsuit Against Bolt Biotherapeutics Inc

Accesswire September 5, 2024

Bolt Biotherapeutics Announces Changes to its Board of Directors

GlobeNewswire September 4, 2024

Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm

Accesswire September 4, 2024

BOLT DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action - BOLT

Newsfile September 3, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT

PR Newswire September 3, 2024

FINAL BOLT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Bolt Biotherapeutics, Inc. Investors to Join the Class Action Lawsuit!

Newsfile September 3, 2024

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Newsfile September 3, 2024

The Schall Law Firm Invites Investors In Bolt Biotherapeutics Inc To Participate In A Securities Fraud Lawsuit

Accesswire September 3, 2024

BOLT FINAL DEADLINE: Bronstein, Gewirtz and Grossman, LLC Reminds Bolt Biotherapeutics, Inc. Shareholders of Final Hours to Lead Class Action!

Accesswire September 3, 2024

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

PR Newswire September 3, 2024

BOLT DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action - BOLT

Newsfile September 2, 2024

FINAL BOLT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Bolt Biotherapeutics, Inc. Investors to Join the Class Action Lawsuit!

Newsfile September 2, 2024

BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Business Wire September 2, 2024

Stakeholders Can Contact The Schall Law Firm About Joining A Case Against Bolt Biotherapeutics Inc. For Securities Law Infractions

Accesswire September 2, 2024

IMMINENT BOLT DEADLINE to Actively Participate in the Class Action Lawsuit for Bolt Biotherapeutics, Inc.: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Last Few Hours!

Accesswire September 2, 2024

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Newsfile September 2, 2024

BOLT DEADLINE NOTICE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action - BOLT

Newsfile September 1, 2024